FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201700890> ?p ?o ?g. }

• W3201700890 abstract "AIMS/BACKGROUND: Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV). Highly active antiretroviral therapy (HAART), is the cornerstone of management of patients with HIV infection. Following the initiation of widespread use of HAART, drug resistance and failure of first line ART is an emerging problem. Hence use of second line ART is on rise, therefore there is a need to study the factors affecting the immunological and virological recovery and specific opportunistic infections during second line ART. In India, the second line regimen has still not been studied extensively when compared to its first line counterpart. This study aims at determining the immunological and virological recovery as well as to study the incidence of various opportunistic infections in HIV/AIDS patients on second line ART.  METHODS: The study was conducted at Bowring & Lady Curzon Hospital, affiliated to Bangalore Medical College from November 2015 to January 2019.The study included 72 patients, switched from first line to second line ART in the year 2015-16 and consented to participate in our study. Patients were analyzed in out-patient as well as in-patient basis, as per need. Clinical assessment was repeated every 6 months for next 3 years. RESULTS: In our study 42 males (58.3%) and 30 females (41.6%) were included. There was a gradual rise in CD4 count from baseline. 81.69% (59) cases had CD4 count 200 at the end of 3 years. Mortality was 5 cases (6.94 %). Among patients who expired, had baseline CD4 Count <100 cells/microliter, stage 3 and 4 at initiation of first line ART. Low CD4 nadir and opportunistic infections during first line ART and T4 stage while switching to second line ART.  CONCLUSION: 1. There was a significant improvement in CD4 Counts and fall in viral load after initiation of Second line ART.2. Severe immunosuppression (CD4 Count <100 cells/microliter) at baseline were associated with low CD4 counts recovery and delayed viral load suppression.FUNDING STATEMENT: None.DECLARATION OF INTERESTS: None.ETHICS APPROVAL STATEMENT: After obtaining ethical clearance and approval from the Institutional Ethics Committee of BMCRI, written informed consent was taken from the patients." @default.
• W3201700890 created "2021-10-11" @default.
• W3201700890 creator A5016458443 @default.
• W3201700890 creator A5086319219 @default.
• W3201700890 date "2020-01-01" @default.
• W3201700890 modified "2023-09-24" @default.
• W3201700890 title "Study of Immunological and Virological Recovery in HIV/AIDS Patients on Second Line Anti-Retroviral Therapy: A Prospective Study" @default.
• W3201700890 doi "https://doi.org/10.2139/ssrn.3742274" @default.
• W3201700890 hasPublicationYear "2020" @default.
• W3201700890 type Work @default.
• W3201700890 sameAs 3201700890 @default.
• W3201700890 citedByCount "0" @default.
• W3201700890 crossrefType "journal-article" @default.
• W3201700890 hasAuthorship W3201700890A5016458443 @default.
• W3201700890 hasAuthorship W3201700890A5086319219 @default.
• W3201700890 hasConcept C120665830 @default.
• W3201700890 hasConcept C121332964 @default.
• W3201700890 hasConcept C126322002 @default.
• W3201700890 hasConcept C142462285 @default.
• W3201700890 hasConcept C187212893 @default.
• W3201700890 hasConcept C188816634 @default.
• W3201700890 hasConcept C203014093 @default.
• W3201700890 hasConcept C2781413609 @default.
• W3201700890 hasConcept C2993143319 @default.
• W3201700890 hasConcept C3013748606 @default.
• W3201700890 hasConcept C61511704 @default.
• W3201700890 hasConcept C71924100 @default.
• W3201700890 hasConceptScore W3201700890C120665830 @default.
• W3201700890 hasConceptScore W3201700890C121332964 @default.
• W3201700890 hasConceptScore W3201700890C126322002 @default.
• W3201700890 hasConceptScore W3201700890C142462285 @default.
• W3201700890 hasConceptScore W3201700890C187212893 @default.
• W3201700890 hasConceptScore W3201700890C188816634 @default.
• W3201700890 hasConceptScore W3201700890C203014093 @default.
• W3201700890 hasConceptScore W3201700890C2781413609 @default.
• W3201700890 hasConceptScore W3201700890C2993143319 @default.
• W3201700890 hasConceptScore W3201700890C3013748606 @default.
• W3201700890 hasConceptScore W3201700890C61511704 @default.
• W3201700890 hasConceptScore W3201700890C71924100 @default.
• W3201700890 hasLocation W32017008901 @default.
• W3201700890 hasOpenAccess W3201700890 @default.
• W3201700890 hasPrimaryLocation W32017008901 @default.
• W3201700890 hasRelatedWork W1093560 @default.
• W3201700890 hasRelatedWork W11509916 @default.
• W3201700890 hasRelatedWork W11571637 @default.
• W3201700890 hasRelatedWork W12291722 @default.
• W3201700890 hasRelatedWork W13696846 @default.
• W3201700890 hasRelatedWork W17127862 @default.
• W3201700890 hasRelatedWork W2284762 @default.
• W3201700890 hasRelatedWork W4424148 @default.
• W3201700890 hasRelatedWork W7529805 @default.
• W3201700890 hasRelatedWork W14353572 @default.
• W3201700890 isParatext "false" @default.
• W3201700890 isRetracted "false" @default.
• W3201700890 magId "3201700890" @default.
• W3201700890 workType "article" @default.